浏览全部资源
扫码关注微信
1.陆军军医大学第一附属医院药学部,重庆 400038
2.重庆医科大学附属儿童医院药学部,重庆 400015
主管药师,硕士。研究方向:临床药学。E-mail:guwr49@163.com
主任药师,博士生导师,博士。研究方向:临床药理学。E-mail:py_xia2013@163.com
纸质出版日期:2023-02-28,
收稿日期:2022-04-14,
修回日期:2023-01-15,
扫 描 看 全 文
谷文睿,杨雅,马欢等.脂质体药物递送系统研究进展及临床应用 Δ[J].中国药房,2023,34(04):508-512.
GU Wenrui,YANG Ya,MA Huan,et al.Research progress and clinical application of liposomal drug delivery system[J].ZHONGGUO YAOFANG,2023,34(04):508-512.
谷文睿,杨雅,马欢等.脂质体药物递送系统研究进展及临床应用 Δ[J].中国药房,2023,34(04):508-512. DOI: 10.6039/j.issn.1001-0408.2023.04.24.
GU Wenrui,YANG Ya,MA Huan,et al.Research progress and clinical application of liposomal drug delivery system[J].ZHONGGUO YAOFANG,2023,34(04):508-512. DOI: 10.6039/j.issn.1001-0408.2023.04.24.
脂质体制剂因具有高效、低毒和靶向等特点,已成为国内外新型药物制剂的研究热点。本文从脂质体的制备方法、分类和临床应用等方面综述近年来的研究进展。结果显示,在制备工艺方面,为了获得更稳定可控的脂质体,学者们在传统制备方法的基础上改进优化,建立了超临界流体法、冷冻干燥法和双不对称离心法等新型制备方法。为实现增强疗效的同时降低毒性的目的,学者们对传统脂质体进行优化,开发出环境敏感型脂质体、长循环脂质体和多功能脂质体等改良脂质体,极大地推动了脂质体在临床的应用。目前脂质体制剂已经在抗肿瘤、抗感染、疫苗等多个领域获得临床应用,但大部分新型脂质体还处于早期的开发阶段。
With the advantage of high efficiency, low toxicity and targeting, liposomes have become the research hotspot of new drug preparations at home and abroad. In this paper, the research progress in recent years is reviewed from the aspects of preparation methods, classification and clinical application of liposomes. The results showed that in order to obtain more stable and controllable liposomes, scholars improved and optimized the traditional preparation methods and established novel preparation methods such as supercritical fluid methods, freeze-drying method and double-asymmetric centrifugation method. In order to enhance the efficacy and reduce toxicity, the conventional liposomes were optimized to get novel ones such as environmentally sensitive liposomes, long-circulating liposomes and multifunctional liposomes, which had greatly promoted the clinical application of liposomes. For now, liposomes have been used in many fields, such as anti-cancer agents, antimicrobial and vaccines, but most of the new liposomes are still in the early stage of development.
脂质体药物递送系统抗肿瘤抗感染疫苗
drug delivery systemanti-cancerantimicrobialvaccine
李建雄,耿爽,胡树坚,等. 脂质体递送系统功能结构设计与应用研究进展[J/OL]. 化工进展,2022:1-12[2022-10-18]. http://dx.doi.org/10.16085/j.issn.1000-6613.2022-1025http://dx.doi.org/10.16085/j.issn.1000-6613.2022-1025.
LOMBARDO D,KISELEV M A. Methods of liposomes preparation:formation and control factors of versatile nanocarriers for biomedical and nanomedicine application[J]. Pharmaceutics,2022,14(3):543.
PRIMOŽIČ M,ČOLNIK M,KNEZ Ž,et al. Advantages and disadvantages of using SC CO2 for enzyme release from halophilic fungi[J]. J Supercrit Fluids,2019,143:286-293.
吴宏华,吴媛,张绘芳. 基于超临界流体强化溶液快速分散技术的冬凌草甲素脂质体口服制剂制备工艺研究[J]. 中国药房,2019,30(10):1361-1365.
CHAKRAVARTY P,FAMILI A,NAGAPUDI K,et al. Using supercritical fluid technology as a green alternative during the preparation of drug delivery systems[J]. Pharmaceutics,2019,11(12):629.
ORTEGA V,GIORGIO S,DE PAULA E. Liposomal formulations in the pharmacological treatment of leishmania-sis:a review[J]. J Liposome Res,2017,27(3):234-248.
YUBA E,OSAKI T,ONO M,et al. Bleomycin-loaded pH-sensitive polymer-lipid-incorporated liposomes for cancer chemotherapy[J]. Polymers(Basel),2018,10(1):74.
BORATTO F A,FRANCO M S,BARROS A L B,et al. Alpha-tocopheryl succinate improves encapsulation,pH-sensitivity,antitumor activity and reduces toxicity of doxorubicin-loaded liposomes[J]. Eur J Pharm Sci,2020,144:105205.
LI M Y,DU C Y,GUO N,et al. Composition design and medical application of liposomes[J]. Eur J Med Chem,2019,164:640-653.
YADAV D,DEWANGAN H K. Pegylation:an important approach for novel drug delivery system[J]. J Biomater Sci Polym Ed,2021,32(2):266-280.
RIVANKAR S. An overview of doxorubicin formulations in cancer therapy[J]. J Cancer Res Ther,2014,10(4):853-858.
张曼玉,楼晨曦,曹傲能. 主动靶向载药脂质体在肿瘤治疗中的研究进展[J]. 生物医学工程学杂志,2022,39(3):633-638.
RODALLEC A,BRUNEL J M,GIACOMETTI S,et al. Docetaxel-trastuzumab stealth immunoliposome:development and in vitro proof of concept studies in breast cancer[J]. Int J Nanomedicine,2018,13:3451-3465.
MOGHIMIPOUR E,REZAEI M,RAMEZANI Z,et al. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil[J]. Eur J Pharm Sci,2018,114:166-174.
王利媛,林华庆,陈靖文,等. 介导基因传递的新型阳离子脂质体的研究[J]. 中国药房,2018,29(15):2152-2156.
赵娜. ApoE修饰阳离子脂质体的制备及其功能的初步研究[D]. 太原:山西医科大学,2016.
EFTEKHARI R B,MAGHSOUDNIA N,SAMIMI S,et al. Co-delivery nanosystems for cancer treatment:a review[J]. Pharm Nanotechnol,2019,7(2):90-112.
WANG J,GONG J B,WEI Z P. Strategies for liposome drug delivery systems to improve tumor treatment efficacy[J]. AAPS PharmSciTech,2022,23(1):27.
YAN W,LEUNG S S,TO K K. Updates on the use of liposomes for active tumor targeting in cancer therapy[J]. Nanomedicine(Lond),2020,15(3):303-318.
HUANG D,SUN L N,HUANG L,et al. Nanodrug deli-very systems modulate tumor vessels to increase the enhanced permeability and retention effect[J]. J Pers Med,2021,11(2):124.
LI C L,ZHAO X,DENG C X,et al. Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect[J]. Int J Pharm,2014,460(1/2):165-172.
WANG W X,SHAO A N,ZHANG N,et al. Cationic polymethacrylate-modified liposomes significantly enhanced doxorubicin delivery and antitumor activity[J]. Sci Rep,2017,7:43036.
MAYER L D,TARDI P,LOUIE A C. CPX-351:a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties[J]. Int J Nanomedicine,2019,14:3819-3830.
GROLL A H,RIJNDERS B J A,WALSH T J,et al. Clinical pharmacokinetics,pharmacodynamics,safety and efficacy of liposomal amphotericin B[J]. Clin Infect Dis,2019,68(Suppl 4):S260-S274.
胡海锦. 两性霉素B制剂的发展及临床应用[J]. 中国合理用药探索,2020,17(7):5-9.
BASSETTI M,VENA A,RUSSO A,et al. Inhaled liposomal antimicrobial delivery in lung infections[J]. Drugs,2020,80(13):1309-1318.
鲁珊珊,魏晓慧. 抗生素脂质体的研究[J]. 中国抗生素杂志,2018,43(8):979-989.
CLANCY J P,DUPONT L,KONSTAN M W,et al. Phase Ⅱ studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection[J]. Thorax,2013,68(9):818-825.
GRIFFITH D E,EAGLE G,THOMSON R,et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by mycobacterium avium complex(CONVERT):a prospective,open-label,rando-mized study[J]. Am J Respir Crit Care Med,2018,198(12):1559-1569.
吴正锋,彭钰君,柏银兰. 疫苗佐剂的研究进展[J/OL]. 微生物学免疫学进展,2022:1-6[2023-01-13]. https://kns.cnki.net/kcms/detail/62.1120.r.20220811.1730.004.htmlhttps://kns.cnki.net/kcms/detail/62.1120.r.20220811.1730.004.html.
WANG N,CHEN M N,WANG T. Liposomes used as a vaccine adjuvant-delivery system:from basics to clinical immunization[J]. J Control Release,2019,303:130-150.
国家药品监督管理局. 重组带状疱疹疫苗获批上市[EB/OL].(2019-05-22)[2022-03-19]. https://www.nmpa.gov.cn/directory/web/nmpa////zhuanti/ypqxgg/gggzjzh/201905-22150701437.htmlhttps://www.nmpa.gov.cn/directory/web/nmpa////zhuanti/ypqxgg/gggzjzh/201905-22150701437.html.
SMALLEY RUMFIELD C,PELLOM S T,MORILLON II Y M,et al. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine[J]. J Immunother Cancer,2020,8(1):e000612.
李平,童智慧,于乐成. 2019冠状病毒病疫苗研究与应用进展[J/OL]. 解放军医学杂志,2022:1-11[2023-01-13].https://kns.cnki.net/kcms/detail/11.1056.R.20220928.1947. 004.htmlhttps://kns.cnki.net/kcms/detail/11.1056.R.20220928.1947.004.html.
林茂铨,李东,褚丽新,等. mRNA疫苗技术概述及新型冠状病毒肺炎mRNA疫苗的研究进展[J]. 中国现代应用药学,2022,39(7):996-1004.
王卡拉.国产新冠mRNA疫苗研发进展如何?两款已在海外获紧急使用授权[N/OL].(2022-12-13)[2023-01-13].https://baijiahao.baidu.com/s?id=1752102351445612351& wfr=spider&for=pchttps://baijiahao.baidu.com/s?id=1752102351445612351&wfr=spider&for=pc.
0
浏览量
5
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构